MedTrace Logo

A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart

NCT04256629 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-01-31

Study results available
· View outcomes & findings →

Summary

This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval

Conditions

  • Healthy Volunteers (Intended Indication: Chronic Kidney Disease)

Interventions

DRUG

Verinurad

Randomized subjects will receive oral dose of verinurad

DRUG

Placebo

Randomized subjects will receive oral dose of placebo

DRUG

Allopurinol

Randomized subjects will receive oral dose of allpurinol (Treatment A and B)

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Thomas Kӧrnicke, MD · PAREXEL Early Phase Clinical Unit Berlin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-03
Primary Completion
2020-08-21
Completion
2020-08-21

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04256629 on ClinicalTrials.gov